RMR Wealth Builders cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 92.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,500 shares of the biopharmaceutical company’s stock after selling 18,517 shares during the period. RMR Wealth Builders’ holdings in Pfizer were worth $243,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of PFE. Natixis grew its position in Pfizer by 528.1% in the 3rd quarter. Natixis now owns 3,814,480 shares of the biopharmaceutical company’s stock worth $139,991,000 after purchasing an additional 3,207,172 shares in the last quarter. Morgan Stanley grew its position in Pfizer by 6.4% in the 3rd quarter. Morgan Stanley now owns 46,069,866 shares of the biopharmaceutical company’s stock worth $1,690,763,000 after purchasing an additional 2,777,676 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in Pfizer by 36.1% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 9,794,442 shares of the biopharmaceutical company’s stock worth $359,457,000 after purchasing an additional 2,599,629 shares in the last quarter. Jupiter Asset Management Ltd. bought a new stake in Pfizer in the 3rd quarter worth about $39,411,000. Finally, First Trust Advisors LP grew its position in Pfizer by 12.8% in the 3rd quarter. First Trust Advisors LP now owns 8,578,720 shares of the biopharmaceutical company’s stock worth $314,839,000 after purchasing an additional 972,021 shares in the last quarter. 67.36% of the stock is owned by institutional investors.
Shares of PFE stock opened at $34.26 on Tuesday. The stock has a market capitalization of $190.43 billion, a P/E ratio of 22.10, a PEG ratio of 2.79 and a beta of 0.70. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. The firm’s 50 day moving average is $35.94 and its 200 day moving average is $37.10. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $43.08.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.46 by ($0.04). The firm had revenue of $11.68 billion for the quarter, compared to the consensus estimate of $11.32 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The business’s revenue was up 11.8% on a year-over-year basis. During the same period last year, the company posted $0.55 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.89 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Investors of record on Friday, January 29th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 4.55%. The ex-dividend date of this dividend is Thursday, January 28th. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s dividend payout ratio is 52.88%.
PFE has been the subject of a number of recent analyst reports. Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 price objective for the company. Morgan Stanley dropped their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Friday, January 29th. The Goldman Sachs Group set a $40.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Thursday, January 21st. DZ Bank reiterated a “buy” rating and issued a $41.00 target price on shares of Pfizer in a research note on Wednesday, February 3rd. Finally, TheStreet upgraded shares of Pfizer from a “c+” rating to a “b-” rating in a research note on Wednesday, November 25th. Eleven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $39.38.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Recommended Story: Stock Symbol
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.